Answers are grounded in this paper and cite their sources.
Background/Objectives: Age may influence intrathecal inflammation and astroglial responses in multiple sclerosis (MS). We explored age-associated differences in cerebrospinal fluid (CSF) biomarkers and peripheral immune-cell populations during diagnostic evaluation, before disease-modifying treatment. Methods: This single-center prospective observational study included 74 participants: 35 treatment-naïve individuals evaluated for demyelinating disease (31 with MS, two with clinically isolated syndrome and two with radiologically isolated syndrome) and 39 non-MS clinical controls. The demyelinating cohort was stratified by age (≤40 years, n = 17; >40 years, n = 18). CSF biomarkers and immune-cell profiles were assessed in assay-specific subsets. Results: In the recovered glial fibrillary acidic protein (GFAP) enzyme-linked immunosorbent assay (ELISA) subset (n = 20; 10 per age group), mean CSF GFAP concentrations were 174.79 ng/mL in participants aged ≤40 years and 295.59 ng/mL in those aged >40 years (exploratory Mann–Whitney p = 0.0312). In the C-X-C motif chemokine ligand 13 (CXCL13)/B-cell-attracting chemokine 1 (BCA1) multiplex subset (n = 19; 10 younger and nine older participants), the corresponding arithmetic means were 140.79 and 4.66 pg/mL (nominal Mann–Whitney p = 0.0403). Spearman correlations with age were ρ = 0.567 (p = 0.0091) for GFAP and ρ = −0.401 (p = 0.0886) for CXCL13. Conclusions: The available observations suggest higher CSF GFAP concentrations with increasing age in this treatment-naïve demyelinating cohort. CXCL13 showed a nominal age-group difference, but the age-continuous association was not statistically significant. Small assay-specific sample sizes and multiple comparisons limit inference.
No takes yet. Share an insight, caveat, or question.
Ruiz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: